文献速递角膜与眼表疾病

预装与非预装DMEK治疗FECD的成本效果分析

Cost-effectiveness analysis of preloaded versus non-preloaded Descemet membrane endothelial keratoplasty for the treatment of Fuchs endothelial corneal dystrophy in an academic centre.
PubMed 文献 · Br J Ophthalmol · 2021-02-26

该回顾性成本效果分析纳入58例Fuchs内皮性角膜营养不良患者,比较预装DMEK(pDMEK,n=38)与非预装DMEK(n-pDMEK,n=30)的成本与效用。结果显示pDMEK成本更低且QALY略高,ICUR与NMB更优,模型经敏感性分析稳健,提示pDMEK具有成本效果和节省成本的优势。

要点

  • pDMEK的QALY为0.6682,n-pDMEK为0.6640。

核心结论

  • 从社会与医疗保健角度看,pDMEK成本更低且产生与n-pDMEK相当的效用值。
  • pDMEK相对于n-pDMEK似乎具有成本效果并节省成本。
  • 需进一步长期随访数据确认这些发现。

研究设计与样本

  • 回顾性成本效果分析,从社会与医疗保健角度开展。
  • 队列为2016至2018年美国马萨诸塞州眼耳医院眼科58例FECD患者,pDMEK组n=38,n-pDMEK组n=30。
  • 排除既往眼手术(除无并发症白内障手术外)、其他角膜移植、青光眼、弱视、激光治疗或任何视网膜/角膜疾病。
  • 主要结局参数为增量成本效用比(ICUR)和净货币效益(NMB),时间跨度为15年。

主要发现

  • pDMEK的QALY为0.6682,n-pDMEK为0.6640。
  • pDMEK临床效果略高(+0.0042 QALY/患者),成本更低(医疗保健:每患者-$1444;社会:每患者-$1457)。
  • pDMEK相比n-pDMEK获得有利的ICUR和NMB。
  • 敏感性分析显示经济模型稳健。

关键数值与推荐

  • pDMEK QALY 0.6682,n-pDMEK QALY 0.6640。
  • 增量QALY +0.0042/患者,增量成本医疗保健-$1444/患者、社会-$1457/患者。

临床怎么用

  • 在FECD患者中,pDMEK可能作为成本更低且效用相当的DMEK方式选择。
  • 决策时可参考pDMEK相对于n-pDMEK的ICUR和NMB优势。
  • 长期随访数据仍需积累以确认成本效果结论。

局限性

  • 回顾性设计。
  • 样本量58例,随访数据有限。
  • 需进一步长期随访数据确认发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To determine the cost-effectiveness of preloaded Descemet membrane endothelial keratoplasty (pDMEK) versus non-preloaded DMEK (n-pDMEK) for the treatment of Fuchs endothelial corneal dystrophy (FECD). METHODS: From a societal and healthcare perspective, this retrospective cost-effectiveness analysis analysed a cohort of 58 patients with FECD receiving pDMEK (n=38) or n-pDMEK (n=30) from 2016 to 2018 in the Department of Ophthalmology, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, USA. Exclusion criteria were previous ocular surgeries (other than uncomplicated cataract surgery), including other keratoplasty procedures, ocular pathological conditions as glaucoma, amblyopia, laser treatments, or any retinal or corneal disease. The main outcome parameters were the incremental cost-utility ratio (ICUR) and net monetary benefit (NMB). RESULTS: pDMEK was less costly compared with n-pDMEK (healthcare: $13 886 vs $15 329; societal: $20 805 vs $22 262), with a slighter greater utility (QALY 0.6682 vs QALY 0.6640) over a time horizon of 15 years. pDMEK offered a slightly higher clinical effectiveness (+0.0042 QALY/patient) at a lower cost (healthcare: -$1444 per patient; societal: -$1457 per patient) in improving visual acuity in this cohort of patients with FECD. pDMEK achieved a favourable ICUR and NMB compared with n-pDMEK. Based on sensitivity analyses performed, the economic model was robust. CONCLUSIONS: From the societal and healthcare perspective, pDMEK was less costly and generated comparable utility values relative to n-pDMEK. Therefore, pDMEK appears to be cost-effective and cost saving with respect to n-pDMEK. Further long-term follow-up data are needed to confirm these findings.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Böhm M, Leon P, Wylęgała A, et al. Cost-effectiveness analysis of preloaded versus non-preloaded Descemet membrane endothelial keratoplasty for the treatment of Fuchs endothelial corneal dystrophy in an academic centre. Br J Ophthalmol. 2021. PMID: 33637619. doi:10.1136/bjophthalmol-2020-317536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。